- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02568306
A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses and Multiple Doses of NNC0165-1562 in Overweight to Obese But Otherwise Healthy Subjects
July 12, 2018 updated by: Novo Nordisk A/S
A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses and Multiple Doses of NNC0165-1562 in Overweight to Obese But Otherwise Healthy Subjects.
This trial is conducted in the United States of America.
The aim of the trial is to investigate safety, tolerability and pharmacokinetics (the exposure of the trial drug in the body) for single doses and multiple doses of NNC0165-1562 in overweight to obese but otherwise healthy subjects.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
93
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Tempe, Arizona, United States, 85283
- Novo Nordisk Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Part I (SD):
- Male, aged 18-55 years (both inclusive) at the time of signing informed consent
- Body mass index (BMI) between 25.0 and 34.9 kg/m^2 (both inclusive). Overweight should be due to excess of adipose tissue, as judged by the investigator
- Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram (ECG) and clinical laboratory tests performed during the screening visit, as judged by the investigator
- Part II (MD):
- Male or female, aged 18-55 years (both inclusive) at the time of signing informed consent
- Body mass index (BMI) between 27.0 and 39.9 kg/m^2 (both inclusive). Overweight should be due to excess of adipose tissue, as judged by the investigator
- Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram (ECG) and clinical laboratory tests performed during the screening visit, as judged by the investigator
Exclusion Criteria:
- Any clinically significant weight change (at least 5% self-reported change during the previous 3 months), dieting attempts (e.g. participation in an organised weight reduction programme within the last 3 months), prior obesity surgery, or medications affecting body weight within 3 months prior to screening
- Male subjects who are not surgically sterilised (vasectomy) and are sexually active with female partner(s) who are not using a highly effective method of contraception (such as condom with spermicide) combined with a highly effective method of contraception for their non-pregnant female partner(s) (Pearl Index 1%, such as implants, injectables, oral contraceptives, intrauterine devices, diaphragm or cervical cap+spermicide), and/or intend to donate sperm in the period from screening until 3 months following administration of the investigational medical product
- Female subjects who are of child bearing potential (pre-menopausal and not surgically sterilised) and are sexually active with male partner(s) who are not surgically sterilised (vasectomy) and are not using highly effective contraceptive methods (Pearl Index 1%,such as implants, injectables, oral contraceptives, intrauterine devices, diaphragm or cervical cap+spermicide) combined with a highly effective method of contraception for their male partner(s) (e.g. condom with spermicide), and/or are pregnant, breast-feeding or intend to become pregnant) (applicable to Part II (MD) only)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Administered subcutaneously (s.c., under the skin) single dose [SD]) or multiple dose [MD] with daily dosing.
|
Experimental: NNC0165-1562
|
Administered subcutaneously (s.c., under the skin) single dose [SD] or multiple dose [MD] with daily dosing.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of treatment emergent adverse events (TEAEs), Part I (SD)
Time Frame: From time of dosing (Day1) until completion of the follow-up visit (Day 29)
|
From time of dosing (Day1) until completion of the follow-up visit (Day 29)
|
Number of TEAEs, Part II (MD)
Time Frame: From time of dosing (Day 1) until completion of the follow-up visit (Day 85)
|
From time of dosing (Day 1) until completion of the follow-up visit (Day 85)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The area under the NNC0165-1562 plasma concentration-time curve, Part I (SD)
Time Frame: From time 0 to 24 hours after a single s.c. dose. From baseline (Day 1) until the follow-up visit (Day 29)
|
From time 0 to 24 hours after a single s.c. dose. From baseline (Day 1) until the follow-up visit (Day 29)
|
The maximum plasma concentration of NNC0165-1562 after a single s.c. dose, Part I (SD)
Time Frame: From baseline (Day 1) until the follow-up visit (Day 29)
|
From baseline (Day 1) until the follow-up visit (Day 29)
|
The time to maximum plasma concentration of NNC0165-1562 after a single s.c.dose, Part I (SD)
Time Frame: From baseline (Day 1) until the follow-up visit (Day 29)
|
From baseline (Day 1) until the follow-up visit (Day 29)
|
The area under the NNC0165-1562 plasma concentration-time curve, Part II (MD)
Time Frame: From time 0 to 24 hours at steady state. From baseline (Day 1) until the follow-up visit (Day 85)
|
From time 0 to 24 hours at steady state. From baseline (Day 1) until the follow-up visit (Day 85)
|
The maximum plasma concentration of NNC0165-1562 at steady state, Part II (MD)
Time Frame: From baseline (Day 1) until the follow-up visit (Day 85)
|
From baseline (Day 1) until the follow-up visit (Day 85)
|
The time to maximum plasma concentration of NNC0165-1562 at steady state, Part II (MD)
Time Frame: From baseline (Day 1) until the follow-up visit (Day 85)
|
From baseline (Day 1) until the follow-up visit (Day 85)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 5, 2015
Primary Completion (Actual)
February 7, 2017
Study Completion (Actual)
February 7, 2017
Study Registration Dates
First Submitted
October 2, 2015
First Submitted That Met QC Criteria
October 2, 2015
First Posted (Estimate)
October 5, 2015
Study Record Updates
Last Update Posted (Actual)
July 13, 2018
Last Update Submitted That Met QC Criteria
July 12, 2018
Last Verified
July 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NN9747-4194
- U1111-1164-6546 (Other Identifier: WHO)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Fundació Sant Joan de DéuNot yet recruitingObesity, Childhood | Obesity, AdolescentSpain
Clinical Trials on NNC0165-1562
-
Novo Nordisk A/SCompletedOverweight or Obesity | Metabolism and Nutrition DisordersUnited States
-
Novo Nordisk A/SCompletedObesity and OverweightUnited States
-
Novo Nordisk A/SCompleted
-
Debiopharm International SACompletedDiffuse Large B-Cell Lymphoma | B-cell Non-Hodgkin's LymphomaUnited States, Czechia, Belgium, Hungary, Ukraine, Bulgaria, Italy, Poland, Switzerland